Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunology
Biotech
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.
James Waldron
Oct 24, 2025 9:15am
Nilo launches with $101M and mission to harness neural circuits
Oct 8, 2025 9:55am
AstraZeneca, Algen Biotechnologies pen $555M AI pact
Oct 6, 2025 8:00am
Sanofi's R&D chief 'pretty pragmatic' about clinical setbacks
Sep 17, 2025 8:01am
AbbVie ends development of IL-1 asset in ulcerative colitis
Jul 31, 2025 12:32pm
Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies
Jul 16, 2025 1:37pm
